for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Ltd (ADR)

TEVA.N

Latest Trade

8.99USD

Change

-0.02(-0.22%)

Volume

788,227

Today's Range

8.97

 - 

9.27

52 Week Range

6.25

 - 

13.76

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
9.01
Open
9.06
Volume
788,227
3M AVG Volume
185.22
Today's High
9.27
Today's Low
8.97
52 Week High
13.76
52 Week Low
6.25
Shares Out (MIL)
1,095.78
Market Cap (MIL)
9,864.69
Forward P/E
3.53
Dividend (Yield %)
--

Next Event

Q3 2020 Teva Pharmaceutical Industries Ltd Earnings Release

Latest Developments

More

Collegium Announces Settlement With Teva Resolving Xtampza Er Patent Litigation

Alkermes Files Lawsuit Against Teva USA & Teva Pharmaceutical Industries

Teva Pharma Finance Netherlands Offering To Exchange Upto €1 Bln Of 6% Senior Notes

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Teva Pharmaceutical Industries Ltd (ADR)

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Industry

Biotechnology & Drugs

Contact Info

5 Bazel St, P O B 3190

49131

Israel

+972.3.9267267

http://www.tevapharm.com

Executive Leadership

Sol J. Barer

Independent Chairman of the Board

Kaare Schultz

President, Chief Executive Officer, Director

Eliyahu Sharon Kalif

Chief Financial Officer, Executive Vice President

Mark Sabag

Executive Vice President, Chief Human Resources Officer and Global Communications and Brand

Richard Daniell

Executive Vice President - European Commercial

Key Stats

2.83 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.4K

2018

18.9K

2019

16.9K

2020(E)

16.8K
EPS (USD)

2017

4.010

2018

2.920

2019

2.400

2020(E)

2.510
Price To Earnings (TTM)
3,478.76
Price To Sales (TTM)
0.60
Price To Book (MRQ)
0.71
Price To Cash Flow (TTM)
6.60
Total Debt To Equity (MRQ)
189.61
LT Debt To Equity (MRQ)
177.71
Return on Investment (TTM)
-0.33
Return on Equity (TTM)
-0.25

Latest News

Latest News

New York charges Johnson & Johnson with insurance fraud over opioid claims

New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.

U.S. charges Teva in generic drugs price-fixing probe

The U.S. Justice Department charged Teva Pharmaceutical Industries Ltd on Tuesday with conspiring with competitors to raise prices for generic drugs.

U.S. charges founder of drug company bought by Teva in insider trading case

U.S. prosecutors brought insider trading charges against the founder and former chief executive of Auspex Pharmaceuticals Inc, accusing him of providing illegal tips to friends and family as Teva Pharmaceutical Industries Ltd <TEVA.TA> prepared to buy his company in a $3.5...

US charges ex-CEO of drug company with fraud tied to Teva tender offer

U.S. prosecutors on Tuesday announced insider trading charges accusing the former chief executive of Auspex Pharmaceuticals Inc with tipping friends and family about an anticipated tender offer for his company by Teva Pharmaceutical Industries Ltd in 2015.

U.S. to charge Teva in generic drugs price-fixing probe: Bloomberg Law

U.S. Justice Department is preparing to charge Teva Pharmaceutical Industries Ltd with conspiring with competitors to raise prices for generic drugs, Bloomberg Law reported on Tuesday citing a person familiar with the matter.

New York charges Teva, Allergan with insurance fraud over opioid claims

New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd and Allergan Plc with insurance fraud for downplaying the risks of their opioid painkillers to patients and doctors.

New York files insurance fraud charges against opioid makers Teva, Allergan

New York Governor Andrew Cuomo said on Tuesday the State Department of Financial Services had filed charges against Teva Pharmaceuticals and Allergan Plc over their role in the opioid crisis.

U.S. sues Teva over alleged kickbacks for multiple sclerosis drug

The U.S. government sued Teva Pharmaceutical Industries Ltd <TEVA.TA> on Tuesday, accusing the drugmaker of causing the submission of false claims to Medicare by using kickbacks to boost sales of its multiple sclerosis drug Copaxone.

U.S. sues Teva over alleged kickbacks for multiple sclerosis drug

REUTERS - The U.S. government sued Teva Pharmaceutical Industries Ltd on Tuesday, accusing the drugmaker of causing the submission of false claims to Medicare as a result of kickbacks it paid for its multiple sclerosis drug Copaxone.

Pharmacy to pay $3.5 million to resolve U.S. claims it helped Teva pay kickbacks

A Florida-based specialty pharmacy will pay $3.5 million to resolve allegations it served as a conduit for a Teva Pharmaceutical Industries Ltd subsidiary to pay kickbacks to Medicare patients, the U.S. Justice Department said on Thursday.

Teva Pharm second-quarter profit tops forecast, reaffirms 2020 outlook

Teva Pharmaceutical Industries' <TEVA.TA> quarterly profit beat estimates by two cents and the company reaffirmed its outlook for 2020 despite uncertainty generated by the COVID-19 crisis.

BRIEF-Teva Presents New Analyses Examining Changes In Migraine Disability Outcome Measurements With Ajovy Injection

* TEVA PRESENTS NEW ANALYSES EXAMINING CHANGES IN MIGRAINE DISABILITY OUTCOME MEASUREMENTS WITH AJOVY® (FREMANEZUMAB-VFRM) INJECTION

BRIEF-Teva To Present New Data On Ajovy Injection Open-Label Extension Study

* TEVA TO PRESENT NEW DATA ON AJOVY® (FREMANEZUMAB-VFRM) INJECTION OPEN-LABEL EXTENSION STUDY AT AMERICAN HEADACHE SOCIETY ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Teva Pharmaceutical Shareholders Approve Amendment To Terms Of Office And Employment Of CEO

* TEVA PHARMACEUTICAL INDUSTRIES - SHAREHOLDERS APPROVED AMENDMENT NO. 1 TO TERMS OF OFFICE AND EMPLOYMENT OF CO'S CEO KÅRE SCHULTZ AT ANNUAL MEETING

EU antitrust regulators reinforce case against Teva pay-for-delay deals

EU antitrust enforcers, boosted by recent court victories, on Monday reinforced their case against Israeli drugmaker Teva over its deal with rival Cephalon to delay selling a generic version of its sleep disorder drug modafinil.

BRIEF-FDA Says Teva Recalling 14 Lots Of Metformin Hydrochloride Extended-Release Tablets

* US FDA SAYS TEVA RECALLING 14 LOTS OF METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, USP 500 MG AND 750 MG, DUE TO DETECTION OF EXCESS NDMA LEVELS Source text : https://bit.ly/2zYnSAl Further company coverage:

Israel's Teva gets China approval for Huntington's treatment

Teva Pharmaceutical said on Monday that China has given the go-ahead to its Austedo treatment for Huntington's disease.

Teva Pharm gets approval in China for Huntington's treatment

China has given the greenlight to Teva Pharmaceutical Industries' <TEVA.N> Austedo treatment for Huntington's disease, the company said on Monday.

UPDATE 3-Teva Pharmaceutical's profit beats forecasts, shares jump

* Shares jump almost 20% (Adds CEO comments on migraine drug, contract extension)

BRIEF-Teva Reports Q1 Non-GAAP Earnings Per Share $0.76

* REVENUES FROM NORTH AMERICA SEGMENT IN Q1 OF 2020 WERE $2,082 MILLION, AN INCREASE OF $36 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up